In a Phase 1-2 trial of Regenxbio's RGX-314 gene therapy for age-related macular degeneration, levels of an antibody produced by the treatment, which blocks a protein that causes AMD, hadn't diminished in one patient group two years after injection of the drug, and patients at the highest dose cohort experienced an improvement in their vision six months after injection. "New Treatments for Macular Degeneration Are on the Way," at 7:34 p.m. ET on June 8, incorrectly gave the time frame over which the antibody levels hadn't fallen as 18 months, and didn't include the time frame for improved vision in the highest dose cohort. Also, Regenxbio now plans to begin Phase 3 trials of RGX-314 this year. The article said the company planned to start Phase 3 trials by early next year.